Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses.
about
Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipientsManagement of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignanciesInfluenza prevention and treatment in transplant recipients and immunocompromised hostsFourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirusChallenges and opportunities in developing respiratory syncytial virus therapeuticsHow I treat influenza in patients with hematologic malignancies.Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients.Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT.Pre-hematopoietic stem cell transplant lung function and pulmonary complications in children.Innate immune activation by the viral PAMP poly I:C potentiates pulmonary graft-versus-host disease after allogeneic hematopoietic cell transplant.Pleuropericarditis, obliterative bronchiolitis and lymphocytic interstitial pneumonitis after allogeneic haematopoietic stem cell transplantation.Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host diseaseEvaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantationBlood and marrow transplant clinical trials network state of the Science Symposium 2014Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection.Comparison of the Luminex xTAG RVP Fast assay and the Idaho Technology FilmArray RP assay for detection of respiratory viruses in pediatric patients at a cancer hospital.Management of respiratory viral infections in hematopoietic cell transplant recipients.Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement.How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantationSymptomatic parainfluenza virus infections in children undergoing hematopoietic stem cell transplantation.High-resolution CT findings of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantationThe challenge of respiratory virus infections in hematopoietic cell transplant recipients.Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation.Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.Lower Respiratory Tract Diseases Caused by Common Respiratory Viruses among Stem Cell Transplantation Recipients: A Single Center Experience in Korea.Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.Viral pneumonias in immunocompromised adult hosts.Preventing and managing bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation.Current management of parainfluenza pneumonitis in immunocompromised patients: a review.Clinical relevance of natural killer cells following hematopoietic stem cell transplantation.Bone marrow transplantation alters lung antigen-presenting cells to promote TH17 response and the development of pneumonitis and fibrosis following gammaherpesvirus infection.Antiviral therapy for respiratory viral infections in immunocompromised patients.Viral Pneumonia in Patients with Hematologic Malignancy or Hematopoietic Stem Cell Transplantation.Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients.Characterizing the Cellular Immune Response to Parainfluenza Virus 3.Parainfluenza Virus 3-Specific T Cells: Opportunity for Intervention?Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment.RSV infection without ribavirin treatment in pediatric hematopoietic stem cell transplantation.Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation.Influenza vaccination in oncology patients.
P2860
Q26829188-A0CFD88F-F9CA-43EC-8694-A2AEE264C10EQ26853131-BAAA8260-F453-4FB9-AAA4-C645DC2021C7Q27011595-A360CA75-4334-4C7D-B2CE-AB1D41DAA5A4Q27021622-845CFB8F-8980-4999-8106-091B032DEBCEQ30300567-788DCAEC-4708-4273-8D12-4DEAFF068986Q30383456-8CBBB243-12CF-4BAD-A54F-2C4BB8A63EFEQ30403699-0095A0C8-18F6-4FC9-9744-F0B2C39E3D47Q33785773-41674A86-A169-47F0-ACC0-3EE7A9B0706CQ33811274-01285B0F-F803-4B36-B416-7FF75A391EFEQ34462078-A6B5EAB4-1D40-4AED-91AF-CFA6C02DC51AQ34710745-C48C5EB0-64B6-4FE6-A6F3-B5508E2C071AQ35293711-A78357FA-1D2B-4016-A4E1-13E9BFD55339Q35574785-6B3ACF2B-D1AD-4522-BE8D-B7585C4DE0A5Q35591760-6D35CC6D-44DC-440E-892B-387EE2AAE14BQ35989482-97CC7F8A-AAE9-4C1F-8A47-7711D927FE3CQ36118576-86C8EF67-3F2F-4D42-8039-1ED8CFFC7AAEQ36439896-299C21F0-64DE-4DF3-BE54-F2E64C7C58D6Q36886930-D7F35F85-8E99-48AE-ADE7-4284A69CDC60Q36965855-FAEDF484-1F62-4ADF-8328-FDF7338596B4Q37074844-AD787B81-E3DD-4758-8ACC-F10F0ED01F33Q37093836-D1D56C7E-2DC2-44D9-9CD8-A3167C796523Q37266577-DE4518DB-D0B8-43D6-B176-4206F7B6031FQ37284406-2B9F72F6-0C63-48E8-AD50-58CE4745EEE5Q37426542-60764328-AC88-443A-84EA-5F32A88D96EAQ37622157-1C7E11AE-C266-4967-93E3-2527B36C362CQ37680499-EFB421AF-622B-4CAF-B1CC-CF71FFE6BAFCQ37788451-86AE332D-40CF-437E-84A4-DAD5EB5A22DBQ37846706-1308B055-7B6D-4680-B3F6-C8945D62E43EQ38034753-3D28190E-C64A-4B51-9364-6BCAF6AC367FQ38079585-A6C59E95-B5BD-45AB-A09B-651A5CC9B7A1Q39052615-B648E924-6002-494B-A694-D0CC95EC8855Q39076394-A986ACCA-7DFD-400B-94A1-27117B4D576AQ39118448-A42E6101-3D7B-4F9B-8ACB-C8DDD28B7AA1Q39973043-40B2E7E9-5D4E-4DCB-8DD8-2431FAB7EA25Q40215048-07905932-885D-4C73-9442-6057FD08D0BCQ40215133-082FB130-EF85-4400-A650-C5CE47487669Q40385568-92B2ABC1-9814-4493-A76E-9264BC57CB1EQ40673394-ED5BA4F0-4D0B-424B-B026-0EEB78C03536Q41166298-8195CEF6-5524-43EA-A114-754DF4C07158Q42239906-6FE50743-02E9-43AA-BEF9-FBE57F4516CF
P2860
Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Airflow decline after myeloabl ...... community respiratory viruses.
@en
Airflow decline after myeloabl ...... community respiratory viruses.
@nl
type
label
Airflow decline after myeloabl ...... community respiratory viruses.
@en
Airflow decline after myeloabl ...... community respiratory viruses.
@nl
prefLabel
Airflow decline after myeloabl ...... community respiratory viruses.
@en
Airflow decline after myeloabl ...... community respiratory viruses.
@nl
P2093
P356
P1476
Airflow decline after myeloabl ...... community respiratory viruses.
@en
P2093
Hyung W Kim
Jason W Chien
Mary E Flowers
Paul J Martin
Veronique Erard
W Garrett Nichols
P304
P356
10.1086/504268
P407
P577
2006-05-10T00:00:00Z